We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-9.72%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$637M
AUM Growth
-$173M
Cap. Flow
-$30.7M
Cap. Flow %
-4.82%
Top 10 Hldgs %
65.73%
Holding
51
New
1
Increased
5
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$2.81M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.74M
3
TNGX icon
Tango Therapeutics
TNGX
+$2.4M
4
ALLK
Allakos
ALLK
+$2.31M
5
ELEV
Elevation Oncology
ELEV
+$11

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$7.21M
2
JANX icon
Janux Therapeutics
JANX
+$5.64M
3
CHFW.U
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
+$3.12M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.48M
5
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.27%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.7M 0.89%
711,039
– –
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
$5.38M 0.84%
549,250
– –
EQ icon
28
Equillium
EQ
$133M
$5.03M 0.79%
738,176
– –
JYAC
29
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.94M 0.78%
507,041
– –
DAWN
30
DELISTED
Day One Biopharmaceuticals
DAWN
$4.8M 0.75%
202,500
– –
EYPT icon
31
EyePoint Inc
EYPT
$1.2B
$4.69M 0.74%
450,000
– –
RYTM icon
32
Rhythm Pharmaceuticals
RYTM
$7.96B
$3.92M 0.62%
300,293
– –
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$3.12M 0.49%
100,000
– –
TERN
34
DELISTED
Terns Pharmaceuticals
TERN
$3.01M 0.47%
289,068
– –
BLSA
35
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.99M 0.47%
300,000
– –
BCEL
36
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.47M 0.39%
396,835
– –
IMCR icon
37
Immunocore
IMCR
$1.73B
$2.37M 0.37%
64,000
– –
SRZN icon
38
Surrozen
SRZN
$301M
$2.12M 0.33%
+20,000
New +$2.81M
KLRS
39
Kalaris Therapeutics
KLRS
$96.8M
$2.06M 0.32%
3,580
– –
ODT
40
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.04M 0.32%
700,421
– –
KRON
41
DELISTED
Kronos Bio
KRON
$1.64M 0.26%
78,131
– –
KALA icon
42
KALA BIO
KALA
$14.5M
$1.57M 0.25%
241
– –
BNTX icon
43
BioNTech
BNTX
$23.5B
$1.57M 0.25%
5,758
– –
VTGN icon
44
VistaGen Therapeutics
VTGN
$12.8M
$1.34M 0.21%
16,288
-8,132
-33% -$707K
RCKT icon
45
Rocket Pharmaceuticals
RCKT
$394M
$1.21M 0.19%
40,550
– –
NGM
46
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$287K 0.05%
13,669
-4,556
-25% -$100K
ATXS
47
DELISTED
Astria Therapeutics
ATXS
$221K 0.03%
25,000
– –
AMRN
48
Amarin Corp
AMRN
$303M
$128K 0.02%
1,250
– –
ALPN
49
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-275,169
Closed -$2.48M
SNCE
50
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-10,000
Closed -$2M
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2021 Portfolio in Review

As of Q3 2021, Samsara BioCapital held 51 positions worth $637M, down 21% from $810M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Samsara BioCapital withdrew a net $30.7M in Q3 2021, closing 3 positions and reducing 8 holdings. Its most notable exit was Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third, an estimated $3.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Surrozen worth $2.12M.

  • Samsara BioCapital's largest Q3 2021 buy was Surrozen: 20,000 shares worth $2.12M.
  • Samsara BioCapital added most to Chinook Therapeutics, Inc. Common Stock in Q3 2021, an estimated $2.74M increase.
  • Samsara BioCapital's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $7.21M.
  • Samsara BioCapital fully exited Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third in Q3 2021, selling an estimated $3.12M.
  • Samsara BioCapital's ten largest holdings make up 66% of its $637M portfolio in Q3 2021.
  • Samsara BioCapital opened 1 new position and closed 3 in Q3 2021.
  • Samsara BioCapital's portfolio value fell 21% quarter-over-quarter to $637M.

Based on Samsara BioCapital's 13F filing for Q3 2021, filed 15 Nov 2021.